Salman Dahlia, Swinden Julian, Barton Stephen, Peron Jean-Marie R, Nabhani-Gebara Shereen
School of Pharmacy and Chemistry, Faculty of Science, Engineering and Computing, Kingston University, London
School of Pharmacy and Chemistry, Faculty of Science, Engineering and Computing, Kingston University, London.
J Oncol Pharm Pract. 2016 Feb;22(1):86-91. doi: 10.1177/1078155214549490. Epub 2014 Sep 1.
This paper aims to summarise and critically review the existing published literature with regard to clinical considerations as well as stability testing studies of Ifosfamide and Mesna. It also aims to highlight the factors that should be considered when designing and conducting stability testing experiments.
Ifosfamide and Mesna are currently given to patients for 14 days continuous home-based infusion for the treatment of soft tissue sarcoma. No previous work has evaluated their stability for more than 7 days under real-life conditions so the current regimen involves patients visiting hospital twice during the 14-day treatment. This may create extra disruption to patients' life style as well as increasing the workload for cancer services.
There is a need to conduct stability testing experiments for Ifosfamide and Mesna taking into consideration all of the highlighted factors to mimic standard clinical practice.
本文旨在总结并批判性地回顾关于异环磷酰胺和美司钠的临床考量以及稳定性测试研究的现有已发表文献。它还旨在强调在设计和进行稳定性测试实验时应考虑的因素。
目前，异环磷酰胺和美司钠给予患者进行为期14天的持续居家输注，用于治疗软组织肉瘤。以前没有研究在现实生活条件下评估过它们超过7天的稳定性，因此目前的治疗方案要求患者在14天的治疗期间两次前往医院。这可能会给患者的生活方式带来额外干扰，并增加癌症服务的工作量。
有必要针对异环磷酰胺和美司钠进行稳定性测试实验，同时考虑所有强调的因素，以模拟标准临床实践。
